Medical News

RSS

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the David H. Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) today announced the publication of new data in the journal Proceedings of the National Academy of Sciences (PNAS) describing further advancements in discovery and development of novel “lipidoid” formulations for the systemic delivery of RNAi therapeutics.

30 Dec 2009

Researchers develop automated system to differentiate strains of influenza

Researchers from the Medical College of Wisconsin, the Children's Research Institute, and the Children's Hospital of Wisconsin have developed a rapid, automated system to differentiate strains of influenza.

30 Dec 2009

FDA impersonators threaten and extort victims who purchase drugs over the Internet

The U.S. Food and Drug Administration is warning the public about criminals posing as FDA special agents and other law enforcement personnel as part of an international extortion scam.

30 Dec 2009

Scientists develop straightforward technique to find ethnic origin of stem cells

An international team of scientists led by researchers at The Scripps Research Institute has developed a straightforward technique to determine the ethnic origin of stem cells.

30 Dec 2009

Acupuncture also improves sex drive while reducing hot flashes in breast cancer patients

Not only is acupuncture as effective as drug therapy at reducing hot flashes in breast cancer patients, it has the added benefit of potentially increasing a woman's sex drive and improving her sense of well-being, according to a Henry Ford Hospital study.

30 Dec 2009

TRAP-1 may prevent cancer cell death, current research suggests

Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, "Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer," appears in the January 2010 issue of the American Journal of Pathology.

30 Dec 2009

Majority of small business owners do not support public health care option

Eighty-three percent of the owners of small businesses surveyed across Michigan do not support a government-operated health care plan as a public option for insurance, according to a new survey of the members of the Michigan Business and Professional Association (MBPA) and the Michigan Food and Beverage Association (MFBA) headquartered in Warren. This is intriguing data as Michigan's economy has been under national scrutiny and the bills were designed to help small business.

30 Dec 2009

Arigene to terminate tender offer for all of Trimeris’ outstanding shares of common stock

Trimeris, Inc. (“Trimeris”) today announced that in connection with the Agreement and Plan of Merger dated October 2, 2009, as amended, by and among Trimeris, Arigene Co., Ltd. and RTM Acquisition Company (“Arigene” and “Purchaser,” respectively) (the “Merger Agreement”), Arigene has informed Trimeris through counsel that Arigene intends to terminate the tender offer for all of Trimeris’ outstanding shares of common stock because Arigene was unable to secure sufficient financing for purposes of funding the tender offer. The tender offer expired on Monday, December 28, 2009.

30 Dec 2009

Walgreens offers H1N1 vaccinations at all of its pharmacies throughout Massachusetts

Walgreens, the nation’s largest drugstore chain and industry leader with more than 17,000 certified or licensed immunizers, is now offering H1N1 vaccinations at all of its pharmacies throughout Massachusetts.

30 Dec 2009

Phase 3 trial of figitumumab discontinued by Pfizer

Pfizer Inc. announced today the discontinuation of A4021016 (also known as ADVIGO 1016), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC) due to the study meeting predefined boundaries for early termination.

30 Dec 2009

Spectranetics illegally imports unapproved medical devices, agrees to pay $5M for resolving allegations

Spectranetics Corporation, a medical device manufacturer, has agreed to pay the United States $4.9 million in civil damages plus a $100,000 forfeiture to resolve claims against the company, the Justice Department announced today. The claims arise from allegations that the company illegally imported unapproved medical devices and provided them to physicians for use in patients, conducted a clinical study in a manner that failed to comply with federal regulations and promoted certain products for procedures for which the company had not received Food and Drug Administration approval or clearance.

30 Dec 2009

UC researchers receive $2.5 million grant to study treatment for voice disorders

For patients with severe voice disorders, the loss of their voice often means losing their social life, self esteem or livelihood. While existing therapies can treat mild to moderate voice disorders, physicians have a harder time determining effective treatments for those with severe cases.

30 Dec 2009

VIVUS submits a NDA to the FDA for obesity drug Qnexa

VIVUS, Inc., a biopharmaceutical company developing innovative, next-generation medical therapies to address unmet needs in obesity, diabetes and sexual health, announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of Qnexa, its investigational drug for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity.

30 Dec 2009

NeurAxon closes the sale of $8.75 million of unsecured subordinated convertible debentures

NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed the sale of approximately $8.75 million of unsecured subordinated 2.0% convertible debentures that are convertible under specified circumstances into existing class B preferred shares.

29 Dec 2009

VIA Pharmaceuticals receives NASDAQ delisting notice

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on December 29, 2009, it received a written notice from the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on January 4, 2010 and that NASDAQ would initiate procedures to delist the Company's common stock.

29 Dec 2009

Xin Aoxing Oleanolic Acid Capsules for treatment of Hepatitis B to be launched

Biostar Pharmaceuticals, Inc. ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced it has completed preparation to launch its flagship Xin Aoxing Oleanolic Acid ("Xin Aoxing") Capsules for the treatment of Hepatitis B in Beijing and Shanghai in early January 2010.

29 Dec 2009

Luna Innovations acquires intellectual property assets of Tego Biosciences

Luna Innovations Incorporated has acquired certain intellectual property assets of Tego Biosciences, its main competitor in developing medicines based on carbon nanomaterials.

29 Dec 2009

Healthcare management application targeting MS patients released

A Pennsylvania-based company has just released a healthcare management application that targets Multiple Sclerosis (MS) patients to the App Store.

29 Dec 2009

H1N1 vaccine currently available at all seven Target Clinic locations in Maryland

Target® announces today that the H1N1 vaccine is currently available at all seven Target Clinic locations in Maryland, while supplies last.

29 Dec 2009

Pre-market approval by FDA of cardiovascular devices often based on studies that lack adequate strength

Pre-market approval by the FDA of cardiovascular devices is often based on studies that lack adequate strength or may have been prone to bias, according to a study in the December 23/30 issue of JAMA. The researchers found that of nearly 80 high-risk devices, the majority received approval based on data from a single study.

29 Dec 2009

Medical News

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Researchers develop automated system to differentiate strains of influenza

FDA impersonators threaten and extort victims who purchase drugs over the Internet

Scientists develop straightforward technique to find ethnic origin of stem cells

Acupuncture also improves sex drive while reducing hot flashes in breast cancer patients

TRAP-1 may prevent cancer cell death, current research suggests

Majority of small business owners do not support public health care option

Arigene to terminate tender offer for all of Trimeris’ outstanding shares of common stock

Walgreens offers H1N1 vaccinations at all of its pharmacies throughout Massachusetts

Phase 3 trial of figitumumab discontinued by Pfizer

Spectranetics illegally imports unapproved medical devices, agrees to pay $5M for resolving allegations

UC researchers receive $2.5 million grant to study treatment for voice disorders

VIVUS submits a NDA to the FDA for obesity drug Qnexa

NeurAxon closes the sale of $8.75 million of unsecured subordinated convertible debentures

VIA Pharmaceuticals receives NASDAQ delisting notice

Xin Aoxing Oleanolic Acid Capsules for treatment of Hepatitis B to be launched

Luna Innovations acquires intellectual property assets of Tego Biosciences

Healthcare management application targeting MS patients released

H1N1 vaccine currently available at all seven Target Clinic locations in Maryland

Pre-market approval by FDA of cardiovascular devices often based on studies that lack adequate strength

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Latest News